CHLORMET TECHNOLOGIES INC. Suite 459 – 409 Granville Street Vancouver, BC, V6C 1T2

Telephone: (604) 678-2531

NEWS RELEASE

Trading Symbol CSE: PUF

Chlormet closes private placement

Vancouver, British Columbia (May 8, 2015) – Chlormet Technologies Inc. ("Chlormet" or the "Company") is pleased to announce that it has closed its non-brokered private placement (see news release dated April 2 and May 1, 2015). The Company has received subscriptions for total proceeds of \$968,300, or for 19,366,000 units (each, a "Unit") at a price of \$0.05 per Unit.

Each Unit consists of one previously unissued common share and one transferable purchase warrant (a "Warrant) of the Company. Each Warrant will entitle the holder, on exercise, to purchase one additional common share of the Company (a "Warrant Share") for a period of 36 (thirty six) months from the date of issue of the Warrant. The Warrants will be exercisable at a price of \$0.075 per share. The warrants will have an acceleration clause such that if after the required hold period the shares in the Company trade above \$0.15 for 10 consecutive trading days, the Company may give notice to the warrant holders that they have 30 days to exercise the warrants.

Chlormet will use the proceeds of the private placement for development of VapeTronix (see news release dated April 2, 2015), Washington State investment opportunity, general working capital and corporate purposes.

Insiders of the Company purchased a total of 1,700,000 units of the financing.

All securities issued pursuant to the placement are subject to a hold period until September 2, 2015 (four months and one day after closing) under applicable Canadian securities laws.

About Chlormet Technologies

Chlormet Technologies Inc. is moving into the Medical Marijuana sector by purchasing a 100% interest in AAA Heidelberg, a private Ontario company that is in the process of applying for a MMPR license. Although the Company cannot guarantee nor estimate the timing for the issuance of a license to AAA Heidelberg, it is Chlormet's goal to become the next publicly traded Canadian company to be granted a new medical marijuana production license.

With the purchase of VapeTronix, the Company plans on rapidly expanding the 1313 brand while driving a near term revenue stream to Chlormet.

ON BEHALF OF THE BOARD OF DIRECTORS

"Yari Nieken"
Interim President and CEO

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.